Miniatura

Fitxers

660519.pdf (520.78 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-09-23

Llicència de publicació

cc-by (c) Conde, Esther et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/118753

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1371/journal.pone.0107200

Resum

Background: Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing discordances between FISH and IHC. The controversy is further fuelled by the different regulatory approvals. This situation prompted us to investigate two ALK IHC antibodies (using a novel ultrasensitive detection-amplification kit) and an automated ALK FISH scanning system (FDA-cleared) in a series of non-small cell lung cancer tumor samples. Methods: Forty-seven ALK FISH-positive and 56 ALK FISH-negative NSCLC samples were studied. All specimens were screened for ALK expression by two IHC antibodies (clone 5A4 from Novocastra and clone D5F3 from Ventana) and for ALK rearrangement by FISH (Vysis ALK FISH break-apart kit), which was automatically captured and scored by using Bioview's automated scanning system. Results: All positive cases with the IHC antibodies were FISH-positive. There was only one IHC-negative case with both antibodies which showed a FISH-positive result. The overall sensitivity and specificity of the IHC in comparison with FISH were 98% and 100%, respectively. Conclusions: The specificity of these ultrasensitive IHC assays may obviate the need for FISH confirmation in positive IHC cases. However, the likelihood of false negative IHC results strengthens the case for FISH testing, at least in some situations

Matèries

Càncer de pulmó, Oncologia

Matèries (anglès)

Lung cancer, Oncology

Citació

Col·leccions

Articles publicats en revistes (Fonaments Clínics)

Citació

CONDE, Esther, SUÁREZ GAUTHIER, Ana, BENITO, Amparo, GARRIDO, Pilar, GARCÍA CAMPELO, Rosario, BISCUOLA, Michele, PAZ-ARES, Luis, HARDISSON, David, CASTRO, Javier de, CAMACHO, María del carmen, RODRÍGUEZ ABREU, Delvys, ABDULKADER, Ihab, RAMÍREZ RUZ, J. (josé), REGUART, Noemí, SALIDO GALEOTE, Marta, PIJUAN, Lara, ARRIOLA APERRIBAY, Edurne, SANZ, Julián, FOLGUERAS, Victoria, VILLANUEVA, Noemí, GÓMEZ ROMÁN, Javier, HIDALGO, Manuel, LÓPEZ RÍOS, Fernando. Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. _PLoS One_. 2014. Vol. 9, núm. 9, pàgs. 107200. [consulta: 25 de febrer de 2026]. ISSN: 1932-6203. [Disponible a: https://hdl.handle.net/2445/118753]

Exportar metadades

JSON - METS

Compartir registre